The impact of comorbidities on costs, utilities and health-related quality of life among HIV patients in a clinical setting in Bogotá

Expert Rev Pharmacoecon Outcomes Res. 2017 Jun;17(3):303-310. doi: 10.1080/14737167.2017.1246185. Epub 2016 Oct 25.

Abstract

Background: This study aimed to assess the impact of comorbidities (CMs) on costs, utilities and health-related quality of life (HRQOL) among HIV patients in Colombia.

Methods: A cross-sectional study was conducted among 138 HIV patients at an outpatient clinic in Bogotá to assess their costs, utilities (EQ5D-5L) and HRQOL (EQ-VAS). CMs and other covariates were gathered from patient records. Multiple regression models were conducted to assess the impact of CMs.

Results: Of all patients, 72% experienced CMs; of these, half experienced ≥2 CMs (N = 49). CMs had a statistically significant impact on utilities when the EQ5D-5L (P = 0.022) was applied among patient with ≥2 CMs. No statistical significance was found for the impact of CMs on costs.

Conclusion: This study suggests that having multiple CMs significantly influences utility, and CMs have some impact on HRQOL measured using the EQ-VAS but this effect is at the border of significance. No significant impact was observed on costs.

Keywords: Acquired Immune Deficiency Syndrome (AIDS); Colombia; Human Immunodeficiency Virus (HIV); bogotá; burden of disease; health-related quality of life (HRQOL); healthcare costs; patient and family costs; utility.

MeSH terms

  • Adult
  • Ambulatory Care / economics*
  • Colombia
  • Comorbidity
  • Cross-Sectional Studies
  • Female
  • HIV Infections / economics
  • HIV Infections / epidemiology*
  • HIV Infections / physiopathology
  • Health Care Costs*
  • Humans
  • Male
  • Middle Aged
  • Quality of Life*
  • Regression Analysis